ERBB3 T355I
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene ERBB3
Variant T355I
Impact List missense
Protein Effect gain of function
Gene Variant Descriptions ERBB3 (HER3) T355I lies within the extracellular domain of the Erbb3 (Her3) protein (UniProt.org). T355I confers a gain of function to the Erbb3 (Her3) protein as demonstrated by increased proliferation of ER-positive cells as compared to wild-type ERBB3 (HER3), increased phosphorylation of downstream signaling molecules, and activation of the MAPK pathway in culture (PMID: 29963236).
Associated Drug Resistance
Category Variants Paths

ERBB3 mutant ERBB3 act mut ERBB3 T355I

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_001982.4
gDNA chr12:g.56088823C>T
cDNA c.1064C>T
Protein p.T355I
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001982 chr12:g.56088823C>T c.1064C>T p.T355I RefSeq GRCh38/hg38
NM_001982.3 chr12:g.56088823C>T c.1064C>T p.T355I RefSeq GRCh38/hg38
NM_001982.4 chr12:g.56088823C>T c.1064C>T p.T355I RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB3 T355I estrogen-receptor positive breast cancer sensitive Fulvestrant + Lapatinib Preclinical - Cell culture Actionable In a preclinical study, the combination therapy of Faslodex (fulvestrant) and Tykerb (lapatinib) resulted in a synergistic effect, demonstrating decreased cell proliferation and reduced colony formation of estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture (PMID: 29963236). 29963236
ERBB3 T355I estrogen-receptor positive breast cancer no benefit Lapatinib Preclinical - Cell culture Actionable In a preclinical study, treatment with Tykerb (lapatinib) did not significantly reduce the proliferation of estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture relative to control and combination treatments (PMID: 29963236). 29963236
ERBB3 T355I estrogen-receptor positive breast cancer no benefit SCH772984 Preclinical - Cell culture Actionable In a preclinical study, treatment with SCH772984 did not significantly reduce the proliferation of estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture relative to control and combination treatments (PMID: 29963236). 29963236
ERBB3 T355I estrogen-receptor positive breast cancer no benefit Lapatinib + SCH772984 Preclinical - Cell culture Actionable In a preclinical study, the combination of Tykerb (lapatinib) and SCH772984 resulted in a synergistic effect, demonstrating decreased colony formation and reduced cell proliferation, but to a lesser degree than Tykerb (lapatinib) combined with Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture (PMID: 29963236). 29963236
ERBB3 T355I estrogen-receptor positive breast cancer no benefit Fulvestrant Preclinical - Cell culture Actionable In a preclinical study, treatment with Faslodex (fulvestrant) did not significantly reduce cell proliferation of estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture relative to control and combination treatments (PMID: 29963236). 29963236
ERBB3 T355I breast cancer sensitive Patritumab deruxtecan Preclinical - Cell culture Actionable In a preclinical study, Patritumab deruxtecan (U3-1402) treatment inhibited growth of a breast cancer cell line expressing ERBB3 (HER3) T355I in culture (PMID: 35503762). 35503762